lactic
acid
bacteria
lab
alongsid
foodbas
platform
util
sinc
therapeut
heterolog
gene
express
abil
lab
elicit
immun
respons
express
foreign
antigen
led
use
potenti
candid
mucos
vaccin
vector
vaccin
vector
offer
sever
attract
advantag
simpl
noninvas
administr
usual
oral
intranas
accept
mainten
genet
modif
low
cost
high
safeti
level
lab
tend
elicit
minim
immun
respons
instead
induc
high
level
system
mucos
antibodi
express
foreign
antigen
follow
uptak
via
mucos
immun
system
lab
use
vaccin
vector
gener
includ
streptococcu
gordonii
lactococcu
lacti
multipl
lactobacillu
speci
gordonii
gener
fallen
use
except
l
lacti
lactobacillu
spp
continu
grow
use
number
public
continu
increas
sever
excel
review
l
lacti
vaccin
publish
well
articl
describ
gener
recombin
bacteria
larg
number
recent
articl
detail
lactobacilli
vaccin
vector
review
focus
public
result
immun
respons
gener
vivo
briefli
review
divid
section
correspond
pathogendiseas
interest
viru
bacterium
pathogen
speci
famili
investig
multipl
studi
ie
human
immunodefici
viru
hiv
escherichia
coli
highlight
focus
immun
respons
result
lactobacillu
vaccin
review
cover
research
involv
lactobacillu
strain
heterolog
gene
express
studi
conduct
unmodifi
lactobacillu
use
either
adjuv
intrins
antibacteri
antivir
properti
exclud
text
review
focus
vivo
immun
respons
select
vitro
studi
signific
immun
compon
tabl
highlight
viral
antigen
tabl
highlight
bacteri
antigen
human
immunodefici
viru
type
releg
statu
treatabl
chronic
diseas
yet
infect
rate
unaccept
high
effect
hiv
vaccin
still
elus
via
tradit
method
statist
signific
limit
plagu
modestli
success
clinic
trial
util
lactobacilli
mucos
vaccin
vector
provid
enhanc
immun
respons
typic
mucos
site
infect
sever
studi
look
lactobacilli
express
hiv
antigen
thu
target
viru
common
site
infect
name
mucosa
laboratori
shown
express
addit
secret
molecul
adjuv
interleukin
salmonella
flagellin
c
significantli
improv
mucos
iga
system
serum
igg
immun
respons
hiv
protein
mper
gag
oral
dose
mice
kuczkowska
et
al
shown
vitro
evid
cell
recruit
use
l
plantarum
strain
express
fusion
protein
gag
challeng
studi
monkey
human
perform
determin
efficaci
immun
respons
altern
prevent
measur
hiv
use
prophylact
topic
microbicid
effect
highrisk
group
incorpor
microbicid
express
lactobacilli
mucos
site
colon
continu
protect
reduc
cost
need
strict
adher
two
separ
studi
lagenaur
et
al
util
vaginaassoci
l
jensenii
strain
secret
cyanovirinn
promis
microbicid
high
affin
hiv
envelop
glycoprotein
applic
safe
rhesu
macaqu
afford
protect
simianhuman
immunodefici
viru
shiv
challeng
group
also
use
lactobacilli
secret
broadli
neutral
antibodi
fragment
protect
vagin
mucosa
though
work
still
perform
vitro
human
trial
way
associ
human
papillomaviru
hpv
variou
cancer
particularli
cervic
cancer
well
known
associ
hpv
protein
usual
express
surfac
cervic
cancer
cell
allow
immun
respons
target
potenti
infecti
viru
also
destroy
infect
cancer
cell
current
two
fdaapprov
vaccin
common
strain
hpv
vaccin
gardasil
cervarix
gener
protect
immun
respons
via
spontan
viruslik
particl
vlp
format
hpv
capsid
protein
vaccin
provid
excel
protect
repres
potenti
cancer
therapi
cost
prove
prohibit
even
unit
state
one
research
group
util
lactobacillu
gener
vlp
use
protein
result
serum
igg
express
follow
subcutan
inject
balbc
mice
research
group
util
surfac
express
hpv
protein
either
minor
capsid
protein
earli
oncoprotein
directli
respons
unregul
cellular
replic
extens
set
earli
experi
poo
et
al
util
l
casei
strain
observ
serum
igg
along
intestin
vagin
iga
oral
immun
mice
also
observ
gamma
interferon
secret
cell
vagina
spleen
well
therapeut
reduct
tumor
size
increas
anim
surviv
follow
tumor
cell
challeng
similar
studi
use
similar
result
poo
et
al
later
target
protein
balbc
mice
observ
serum
igg
mucos
igg
iga
crossneutr
relat
virus
use
l
casei
administ
adachi
et
al
observ
increas
level
cell
gut
well
granzymeb
product
mucos
lymphocyt
found
capabl
cell
lysi
result
also
repeat
anoth
research
group
interestingli
oral
administr
improv
respons
comparison
result
seen
subcutan
intramuscular
administr
anoth
research
group
util
l
plantarum
express
similar
antibodi
antitumor
result
though
check
antibodi
serum
mucosa
observ
therapeut
effect
seen
sever
studi
human
trial
use
cervic
cancer
cervic
intraepitheli
neoplasia
grade
patient
conduct
demonstr
presenc
lymphocyt
cervic
tissu
blood
major
patient
tumor
patholog
downgrad
taken
togeth
data
show
great
promis
potenti
develop
antihpv
lactobacillu
vaccin
meet
import
public
health
need
unpredict
avail
futur
influenza
viru
strain
well
suppli
problem
stem
slow
growth
method
egg
cell
base
mean
antiinfluenza
lactobacillu
vaccin
could
fill
need
particularli
treatment
infect
highli
pathogen
strain
shi
et
al
show
oral
administr
l
plantarum
strain
express
hemagglutinin
ha
induc
fecal
iga
bronchiolar
iga
serum
igg
b
cell
level
secondari
lymphoid
organ
increas
cell
prolifer
secret
greatli
improv
rel
level
seen
typic
influenza
vaccin
importantli
vaccin
mice
surviv
lethal
challeng
result
seen
assay
use
dendrit
celltarget
peptid
dcpep
adjuv
show
improv
immun
respons
challeng
surviv
chicken
similar
antibodi
cell
result
observ
target
hemagglutinin
balbc
mice
chicken
influenza
viru
protein
also
target
chowdhuri
et
al
grant
balbc
mice
protect
via
oral
intranas
administr
multipl
lethal
challeng
strain
show
inclus
cholera
toxin
subunit
significantli
improv
antibodi
level
protect
followup
studi
show
antibodi
level
secret
prolifer
well
protect
lethal
challeng
last
month
postvaccin
recent
outbreak
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
coronaviru
cov
morbid
mortal
gener
wors
domest
anim
rather
human
particularli
within
porcin
poultri
farm
coronavirus
usual
infect
via
gastrointestin
tract
livestock
respiratori
tract
bird
human
caus
devast
econom
loss
danger
morbid
young
old
immunocompromis
first
coronaviru
address
use
lactobacilli
transmiss
gastroenter
coronaviru
tgev
affect
swine
particularli
piglet
sever
spike
protein
epitop
target
result
induct
serum
igg
mucos
iga
mice
recent
muramyl
dipeptid
mdp
protein
target
util
tuftsin
adjuv
result
show
improv
antibodi
cell
respons
balbc
mice
human
coronaviru
address
sarscov
induct
serum
igg
mucos
iga
spike
protein
sa
sb
observ
mice
porcin
epidem
diarrhea
viru
pedv
anoth
coronaviru
primarili
affect
piglet
result
larg
econom
loss
thorough
set
experi
liu
et
al
show
target
spike
protein
nucleocapsid
n
via
surfac
express
rather
via
secret
level
antin
antibodi
significantli
increas
even
atyp
studi
secret
ophthalm
nasal
secret
interestingli
observ
synergi
spike
protein
nucleocapsid
mice
vaccin
protein
improv
immun
respons
tgev
core
neutral
epitop
coe
ge
et
al
fuse
coe
e
coli
enterotoxin
b
ltb
result
show
statist
signific
particularli
respect
splenocyt
secret
perhap
directli
use
studi
hou
et
al
observ
increas
presenc
antinucleocapsid
antibodi
milk
colostrum
nurs
sow
correl
increas
antin
serum
igg
level
suckl
piglet
recent
set
experi
jiang
et
al
delv
deeper
immun
respons
gener
l
casei
highlight
strong
mucosadepend
protect
infect
stimul
pathway
imbal
respons
indic
variat
number
cell
contain
either
intracellular
interestingli
lactobacillu
speci
shown
downregul
respons
simpli
point
delic
balanc
cell
must
strike
pathogenstimul
inflamm
potenti
damag
errant
autoimmun
inflamm
clear
homeostasi
respect
inflamm
immun
lactobacilli
cell
complex
subject
depend
number
factor
includ
host
genet
pathogen
lactobacillu
strain
adjuv
diarrheal
diseas
second
lead
caus
death
children
age
worldwid
rotaviru
respons
hospit
due
diarrheal
ill
estim
rotaviru
kill
approxim
children
world
health
organ
recommend
inclus
rotaviru
vaccin
global
vaccin
protocol
current
two
modifi
live
vaccin
licens
worldwid
global
implement
ongo
countri
data
avail
vaccin
result
reduct
hospit
due
rotaviru
morbid
unfortun
vaccin
limit
efficaci
develop
countri
associ
lowlevel
risk
intussuscept
recombin
lactobacillusbas
vaccin
could
address
need
subunit
rotaviru
vaccin
provid
benefit
probiot
appropri
safeti
profil
use
neonat
infant
two
main
avenu
lactobacillusbas
rotaviru
protect
attempt
mice
first
avenu
use
typic
oral
vaccin
l
casei
induc
mucos
iga
neutral
serum
igg
porcin
rotaviru
major
protect
antigen
pa
mice
second
use
antibodi
fragment
confer
protect
et
al
express
protect
antirotaviru
llama
antibodi
fragment
surfac
l
rhamnosu
protect
diarrhea
mous
pup
model
anoth
group
adapt
use
antirotaviru
hyperimmun
bovin
colostrum
hbc
model
system
express
antihbc
protein
streptococcu
bind
hbc
antibodi
thu
confer
protect
oral
dose
aquacultur
import
food
suppli
paradigm
come
typic
pathogen
problem
largescal
anim
farm
encount
vaccin
fish
pathogen
perform
intraperiton
administr
costprohibit
immers
oral
via
feed
latter
two
option
suffer
lack
vaccin
persist
water
particularli
strong
mucos
toler
observ
fish
comprehens
summari
vaccin
attempt
fish
see
excel
review
embregt
forlenza
lactobacillu
vaccin
vector
provid
effect
easili
administ
system
piscicultur
first
set
studi
target
infecti
pancreat
necrosi
viru
ipnv
birnaviru
afflict
rainbow
trout
direct
oral
administr
l
casei
express
portion
viral
capsid
gener
signific
serum
igm
afford
challeng
protect
two
studi
group
two
virus
primarili
affect
carp
cyprinid
herpesviru
koi
herpesviru
khv
rhabdoviru
carpio
spring
viremia
carp
viru
svcv
also
studi
two
antigen
khv
svcv
glycoprotein
express
togeth
l
plantarum
dose
oral
carp
koi
result
serum
igm
challeng
surviv
data
promis
particularli
vaccin
offer
dual
protect
lactobacillu
studi
must
conduct
look
particular
cellular
mucos
immun
fish
well
potenti
multipl
pathogen
address
singl
modifi
lactobacillu
vaccin
addit
categori
alreadi
address
larg
divers
number
virus
target
use
lactobacillu
vector
system
highlight
rest
detail
tabl
classic
swine
fever
viru
csfv
flaviviru
affect
pig
test
rabbit
mice
pig
test
result
product
serum
mucos
antibodi
importantli
addit
thymosin
cellstimul
peptid
abl
increas
level
igg
iga
tumor
necrosi
factor
alpha
pig
porcin
parvoviru
studi
balbc
mice
pig
excel
igg
iga
respons
well
challeng
protect
viru
neutral
recent
studi
observ
strong
protect
immun
respons
chicken
newcastl
diseas
viru
paramyxoviru
primarili
afflict
poultri
improv
addit
dcpep
boost
mucos
serum
antibodi
level
also
increas
level
helper
cell
spleen
peripher
blood
versu
result
seen
bacteria
without
dcpep
footandmouth
diseas
viru
picornaviru
afflict
clovenhoov
anim
investig
comprehens
dose
studi
assess
anticapsid
immun
respons
result
administr
recombin
l
acidophilu
via
intramuscular
intraperiton
intranas
oral
rout
note
vaccin
strategi
util
bacteria
deliveri
vehicl
capsidexpress
dna
vaccin
plasmid
contrast
util
express
heterolog
protein
bacteria
result
antibodi
respons
thu
much
higher
via
intramuscular
intraperiton
administr
via
mucos
deliveri
eas
use
awar
lactobacillu
express
system
abil
induc
excel
mucos
system
immun
respons
increas
number
varieti
pathogen
address
like
increas
futur
though
infect
rel
rare
preval
natur
bacillu
anthraci
soil
potenti
bioterrorist
agent
give
antianthrax
vaccin
prioriti
protect
antigen
pa
antigen
use
lactobacillu
vaccin
well
studi
test
vaccin
system
variou
degre
success
one
earliest
proofofconcept
lactobacillu
experi
involv
dose
balbc
mice
l
casei
either
oral
intranas
earli
studi
show
antibodi
respons
heterolog
protein
exceed
antibodi
respons
bacteria
ten
year
later
mohamadzadeh
et
al
combin
l
acidophilu
l
gasseri
strain
dcpep
result
neutral
antibodi
challeng
surviv
aj
mice
group
later
observ
colon
dc
activ
regulatori
cell
treg
upregul
upregul
pattern
recognit
receptor
gene
singl
vaccin
dose
enter
escherichia
coli
bacteria
major
caus
diarrheal
morbid
mortal
particularli
children
develop
countri
common
antigen
target
e
coli
vaccin
fimbrial
protein
bacteri
adhesin
aid
host
cell
bind
experi
mention
except
one
target
enterotoxigen
e
coli
etec
prolif
group
china
util
sever
fimbrial
protein
antigen
sever
year
sever
model
balbc
balbc
pup
use
l
casei
among
mani
find
increas
level
sever
subclass
serum
igg
follow
oral
dose
along
increas
level
lesser
increas
level
measur
cell
enzymelink
immunosorb
spot
elispot
assay
intestin
bronchiolar
iga
level
increas
challeng
standard
etec
result
protect
mice
challeng
lethal
dose
studi
repeat
use
intranas
dose
result
decreas
intestin
iga
level
increas
bronchiolar
iga
level
compar
oral
deliveri
dose
mice
induc
similar
igg
iga
respons
well
cell
prolifer
challeng
protect
challeng
protect
confer
mous
pup
born
oral
intranas
immun
dam
wu
chung
target
two
enterotoxin
st
ltb
rather
fimbrial
protein
secret
green
fluoresc
protein
gfp
enterotoxin
fusion
protein
similar
increas
igg
iga
level
observ
well
challeng
protect
patent
mous
gut
assay
ferreira
et
al
group
target
enteropathogen
e
coli
epec
attempt
sublingu
dose
regimen
experi
use
l
casei
express
portion
bacteri
cell
surfac
protein
aid
attach
host
cell
result
serum
igg
fecal
iga
respons
though
interestingli
oral
dose
gener
igg
respons
splenocyt
also
secret
elev
level
though
result
sublingu
vaccin
report
ferreira
et
al
perform
studi
mice
use
mice
challeng
model
due
strain
suscept
citrobact
rodentium
commonli
use
strain
share
patholog
epec
ferreira
et
al
observ
increas
surviv
time
though
anim
eventu
succumb
diseas
lactobacillu
experi
involv
streptococcu
pneumonia
perform
oliveira
laboratori
focus
pneumococc
surfac
protein
either
pspa
pspc
immun
studi
conduct
mice
earli
work
note
signific
increas
bronchiolar
iga
igg
level
follow
intranas
administr
variat
due
bacteri
strain
differ
strategi
increas
antigen
express
result
increas
igg
level
iga
level
measur
enhanc
multipl
igg
subset
challeng
surviv
improv
compar
seen
control
inocul
salin
solut
alon
differ
result
seen
anim
immun
bacteria
express
empti
vector
plasmid
observ
experi
identifi
propens
respons
involv
versu
along
increas
level
low
level
indic
polar
level
secret
neutrophil
recruit
lung
vari
rout
administr
ad
idea
import
manner
vaccin
administ
express
antigen
final
set
experi
fail
induc
signific
level
iga
prior
challeng
research
note
challeng
pneumonia
induc
signific
iga
respons
correl
reduc
bacteri
load
larg
number
pathogen
bacteri
speci
target
lactobacilli
studi
report
research
public
highlight
rest
address
tabl
borrelia
burgdorferi
caus
agent
lyme
diseas
target
l
plantarum
system
result
protect
follow
b
burgdorferiinfect
tick
challeng
author
also
identifi
becom
interest
theme
lactobacillu
vaccin
ie
dual
induct
vitro
work
human
cell
result
cytokin
respons
oral
administr
mice
result
induct
author
also
target
yersinia
pesti
l
plantarum
observ
inflammatori
antiinflammatori
cytokin
indic
stimul
respons
importantli
howev
previou
experi
human
ex
vivo
cytokin
studi
whose
result
confirm
vivo
vaccin
target
helicobact
pylori
common
caus
stomach
ulcer
would
extrem
benefici
target
h
pylori
adhesin
l
acidophilu
strain
hongi
et
al
gener
antiadhes
serum
igg
intestin
iga
reduc
bacteri
load
gastric
inflamm
follow
challeng
antibodi
clostridium
perfringen
identifi
balbc
mice
follow
oral
l
casei
administr
though
statist
signific
antibodi
level
unclear
anim
surviv
challeng
order
combat
pathogen
main
point
entri
nextgener
vaccin
must
establish
protect
mucos
immun
lactic
acid
bacteria
particularli
speci
genu
lactobacillu
shown
great
promis
mucos
vector
capabl
drive
system
mucos
respons
especi
combin
adjuv
number
studi
involv
lactobacilli
steadili
increas
last
year
data
accumul
key
concept
regard
immun
respons
vector
elicit
emerg
interestingli
coinduct
cytokin
point
complex
cell
subset
mucosa
grow
number
studi
suggest
cell
effector
plastic
mucosa
especi
gut
norm
gut
must
strike
balanc
toler
inflamm
appear
one
major
factor
aris
lactobacillu
studi
sinc
evid
inflamm
well
tregbas
toler
point
complex
cell
respons
term
mucos
vaccin
reiter
import
maintain
balanc
wellcharacter
approach
immunogen
work
must
done
identifi
contribut
immun
pathway
within
mucosa
especi
rout
bacteri
uptak
immun
induct
site
cell
dc
sever
major
takeaway
develop
lab
vaccin
platform
continu
safeti
lab
import
strength
enhanc
protect
immunogen
key
challeng
sever
studi
explor
strategi
express
adjuv
cytokin
pathogenassoci
molecular
pattern
toxin
target
molecul
cell
dc
mechanist
understand
strategi
necessari
design
right
combin
immunogen
adjuv
result
protect
rout
administr
typic
oral
lab
effect
type
respons
elicit
due
differ
mucos
induct
site
intrins
differ
strain
lactobacilli
well
locat
antigen
express
surfac
display
intracellular
secret
alter
result
immun
respons
strain
must
therefor
properli
select
specif
antigen
boost
also
clearli
compon
success
vaccin
evid
heterolog
primeboost
strategi
may
improv
least
alter
result
immun
respons
alway
model
system
must
taken
consider
especi
light
new
evid
mucos
immun
differ
two
common
mous
model
balbc
basi
safeti
efficaci
well
overal
cost
lactobacillu
vaccin
vector
hold
great
promis
mucos
vaccin
anticip
use
cluster
regularli
interspac
short
palindrom
repeat
crispr
analysi
allow
sophist
approach
engin
vaccin
candid
ultim
critic
one
candid
success
navig
regulatori
gauntlet
demonstr
efficaci
target
popul
